Enhanced albuminuric response to atrial natriuretic peptide in normoalbuminuric patients with Type 1 diabetes mellitus--a pilot study

What Was Tested

This randomized controlled trial paper looks at ANP (Atrial Natriuretic Peptide).

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, men only.

Eight normoalbuminuric DM patients participated in a three limb, randomized, double-blind, placebo-controlled study.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and pilot study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received ANP (Atrial Natriuretic Peptide).

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

It is described as a pilot, a small early test of whether a larger ANP (Atrial Natriuretic Peptide) study would be practical.

Urine was collected every 15 min for 90 min for the estimation of albumin-creatinine ratio (ACR).

What Was Measured

Topics PubMed links to this paper include Albuminuria, Atrial Natriuretic Factor, Blood Glucose, Blood Pressure, Creatinine, Diabetes Mellitus, Type 1 and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.